Review



gp100 peptides  (AnaSpec)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    AnaSpec gp100 peptides
    Gp100 Peptides, supplied by AnaSpec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gp100+peptide/gp100+peptide/pm40199327-253-63-65
    Average 90 stars, based on 1 article reviews
    gp100 peptides - by Bioz Stars, 2026-10
    90/100 stars

    Images

    Related Articles

    In Vitro:

    Article Title: Non-conventional Inhibitory CD4 + Foxp3 - PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
    Article Snippet: CD8+ T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Article Title: LXR/ApoE activation restricts innate immune suppression in cancer
    Article Snippet: RNA was extracted from MDSCs using the Total RNA Extraction Kit (17200, Noragen), then purified and concentrated using the RNA Clean & Concentrator -5 Kit (R1016, Zymo Research).

    Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity
    Article Snippet: CD8 + T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Transgenic Assay:

    Article Title: Non-conventional Inhibitory CD4 + Foxp3 - PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
    Article Snippet: CD8+ T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Article Title: LXR/ApoE activation restricts innate immune suppression in cancer
    Article Snippet: RNA was extracted from MDSCs using the Total RNA Extraction Kit (17200, Noragen), then purified and concentrated using the RNA Clean & Concentrator -5 Kit (R1016, Zymo Research).

    Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity
    Article Snippet: CD8 + T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Suppression Assay:

    Article Title: Non-conventional Inhibitory CD4 + Foxp3 - PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
    Article Snippet: CD8+ T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Article Title: LXR/ApoE activation restricts innate immune suppression in cancer
    Article Snippet: RNA was extracted from MDSCs using the Total RNA Extraction Kit (17200, Noragen), then purified and concentrated using the RNA Clean & Concentrator -5 Kit (R1016, Zymo Research).

    Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity
    Article Snippet: CD8 + T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Incubation:

    Article Title: Non-conventional Inhibitory CD4 + Foxp3 - PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
    Article Snippet: CD8+ T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Article Title: LXR/ApoE activation restricts innate immune suppression in cancer
    Article Snippet: RNA was extracted from MDSCs using the Total RNA Extraction Kit (17200, Noragen), then purified and concentrated using the RNA Clean & Concentrator -5 Kit (R1016, Zymo Research).

    Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity
    Article Snippet: CD8 + T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Cell Culture:

    Article Title: Non-conventional Inhibitory CD4 + Foxp3 - PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
    Article Snippet: CD8+ T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Article Title: LXR/ApoE activation restricts innate immune suppression in cancer
    Article Snippet: RNA was extracted from MDSCs using the Total RNA Extraction Kit (17200, Noragen), then purified and concentrated using the RNA Clean & Concentrator -5 Kit (R1016, Zymo Research).

    Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity
    Article Snippet: CD8 + T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    In Vivo:

    Article Title: Non-conventional Inhibitory CD4 + Foxp3 - PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
    Article Snippet: CD8+ T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Article Title: LXR/ApoE activation restricts innate immune suppression in cancer
    Article Snippet: RNA was extracted from MDSCs using the Total RNA Extraction Kit (17200, Noragen), then purified and concentrated using the RNA Clean & Concentrator -5 Kit (R1016, Zymo Research).

    Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity
    Article Snippet: CD8 + T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Labeling:

    Article Title: Non-conventional Inhibitory CD4 + Foxp3 - PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
    Article Snippet: CD8+ T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Article Title: LXR/ApoE activation restricts innate immune suppression in cancer
    Article Snippet: RNA was extracted from MDSCs using the Total RNA Extraction Kit (17200, Noragen), then purified and concentrated using the RNA Clean & Concentrator -5 Kit (R1016, Zymo Research).

    Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity
    Article Snippet: CD8 + T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Irradiation:

    Article Title: Non-conventional Inhibitory CD4 + Foxp3 - PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
    Article Snippet: CD8+ T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Article Title: LXR/ApoE activation restricts innate immune suppression in cancer
    Article Snippet: RNA was extracted from MDSCs using the Total RNA Extraction Kit (17200, Noragen), then purified and concentrated using the RNA Clean & Concentrator -5 Kit (R1016, Zymo Research).

    Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity
    Article Snippet: CD8 + T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Activation Assay:

    Article Title: Non-conventional Inhibitory CD4 + Foxp3 - PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
    Article Snippet: CD8+ T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Article Title: LXR/ApoE activation restricts innate immune suppression in cancer
    Article Snippet: RNA was extracted from MDSCs using the Total RNA Extraction Kit (17200, Noragen), then purified and concentrated using the RNA Clean & Concentrator -5 Kit (R1016, Zymo Research).

    Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity
    Article Snippet: CD8 + T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Expressing:

    Article Title: Non-conventional Inhibitory CD4 + Foxp3 - PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
    Article Snippet: CD8+ T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Article Title: LXR/ApoE activation restricts innate immune suppression in cancer
    Article Snippet: RNA was extracted from MDSCs using the Total RNA Extraction Kit (17200, Noragen), then purified and concentrated using the RNA Clean & Concentrator -5 Kit (R1016, Zymo Research).

    Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity
    Article Snippet: CD8 + T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Purification:

    Article Title: Non-conventional Inhibitory CD4 + Foxp3 - PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
    Article Snippet: CD8+ T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Article Title: LXR/ApoE activation restricts innate immune suppression in cancer
    Article Snippet: RNA was extracted from MDSCs using the Total RNA Extraction Kit (17200, Noragen), then purified and concentrated using the RNA Clean & Concentrator -5 Kit (R1016, Zymo Research).

    Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity
    Article Snippet: CD8 + T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Blocking Assay:

    Article Title: Non-conventional Inhibitory CD4 + Foxp3 - PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
    Article Snippet: CD8+ T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Article Title: LXR/ApoE activation restricts innate immune suppression in cancer
    Article Snippet: RNA was extracted from MDSCs using the Total RNA Extraction Kit (17200, Noragen), then purified and concentrated using the RNA Clean & Concentrator -5 Kit (R1016, Zymo Research).

    Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity
    Article Snippet: CD8 + T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Control:

    Article Title: Non-conventional Inhibitory CD4 + Foxp3 - PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
    Article Snippet: CD8+ T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Article Title: LXR/ApoE activation restricts innate immune suppression in cancer
    Article Snippet: RNA was extracted from MDSCs using the Total RNA Extraction Kit (17200, Noragen), then purified and concentrated using the RNA Clean & Concentrator -5 Kit (R1016, Zymo Research).

    Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity
    Article Snippet: CD8 + T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Virus:

    Article Title: Non-conventional Inhibitory CD4 + Foxp3 - PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
    Article Snippet: CD8+ T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Article Title: LXR/ApoE activation restricts innate immune suppression in cancer
    Article Snippet: RNA was extracted from MDSCs using the Total RNA Extraction Kit (17200, Noragen), then purified and concentrated using the RNA Clean & Concentrator -5 Kit (R1016, Zymo Research).

    Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity
    Article Snippet: CD8 + T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Recombinant:

    Article Title: Non-conventional Inhibitory CD4 + Foxp3 - PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
    Article Snippet: CD8+ T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Article Title: LXR/ApoE activation restricts innate immune suppression in cancer
    Article Snippet: RNA was extracted from MDSCs using the Total RNA Extraction Kit (17200, Noragen), then purified and concentrated using the RNA Clean & Concentrator -5 Kit (R1016, Zymo Research).

    Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity
    Article Snippet: CD8 + T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Staining:

    Article Title: Non-conventional Inhibitory CD4 + Foxp3 - PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
    Article Snippet: CD8+ T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Article Title: LXR/ApoE activation restricts innate immune suppression in cancer
    Article Snippet: RNA was extracted from MDSCs using the Total RNA Extraction Kit (17200, Noragen), then purified and concentrated using the RNA Clean & Concentrator -5 Kit (R1016, Zymo Research).

    Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity
    Article Snippet: CD8 + T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Gene Expression:

    Article Title: Non-conventional Inhibitory CD4 + Foxp3 - PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
    Article Snippet: CD8+ T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Article Title: LXR/ApoE activation restricts innate immune suppression in cancer
    Article Snippet: RNA was extracted from MDSCs using the Total RNA Extraction Kit (17200, Noragen), then purified and concentrated using the RNA Clean & Concentrator -5 Kit (R1016, Zymo Research).

    Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity
    Article Snippet: CD8 + T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Knock-Out:

    Article Title: Non-conventional Inhibitory CD4 + Foxp3 - PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
    Article Snippet: CD8+ T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Article Title: LXR/ApoE activation restricts innate immune suppression in cancer
    Article Snippet: RNA was extracted from MDSCs using the Total RNA Extraction Kit (17200, Noragen), then purified and concentrated using the RNA Clean & Concentrator -5 Kit (R1016, Zymo Research).

    Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity
    Article Snippet: CD8 + T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Software:

    Article Title: Non-conventional Inhibitory CD4 + Foxp3 - PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
    Article Snippet: CD8+ T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Article Title: LXR/ApoE activation restricts innate immune suppression in cancer
    Article Snippet: RNA was extracted from MDSCs using the Total RNA Extraction Kit (17200, Noragen), then purified and concentrated using the RNA Clean & Concentrator -5 Kit (R1016, Zymo Research).

    Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity
    Article Snippet: CD8 + T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Emulsion:

    Article Title: Non-conventional Inhibitory CD4 + Foxp3 - PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
    Article Snippet: CD8+ T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Article Title: LXR/ApoE activation restricts innate immune suppression in cancer
    Article Snippet: RNA was extracted from MDSCs using the Total RNA Extraction Kit (17200, Noragen), then purified and concentrated using the RNA Clean & Concentrator -5 Kit (R1016, Zymo Research).

    Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity
    Article Snippet: CD8 + T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Immunofluorescence:

    Article Title: Non-conventional Inhibitory CD4 + Foxp3 - PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
    Article Snippet: CD8+ T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Article Title: LXR/ApoE activation restricts innate immune suppression in cancer
    Article Snippet: RNA was extracted from MDSCs using the Total RNA Extraction Kit (17200, Noragen), then purified and concentrated using the RNA Clean & Concentrator -5 Kit (R1016, Zymo Research).

    Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity
    Article Snippet: CD8 + T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Injection:

    Article Title: Non-conventional Inhibitory CD4 + Foxp3 - PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
    Article Snippet: CD8+ T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.

    Article Title: LXR/ApoE activation restricts innate immune suppression in cancer
    Article Snippet: RNA was extracted from MDSCs using the Total RNA Extraction Kit (17200, Noragen), then purified and concentrated using the RNA Clean & Concentrator -5 Kit (R1016, Zymo Research).

    Article Title: Non-conventional inhibitory CD4 + Foxp3 − PD-1 hi T cells as a biomarker of immune checkpoint blockade activity
    Article Snippet: CD8 + T cells were from the tumor or in vitro cultures of gp100-primed splenocytes (5-day stimulation with gp100 peptide, AnaSpec) from Pmel-1/gp100-specific TCR transgenic mice.



    Similar Products

    human medchemexpress hy p70543 human gp100 peptide  (MedChemExpress)
    95
    MedChemExpress human medchemexpress hy p70543 human gp100 peptide
    Human Medchemexpress Hy P70543 Human Gp100 Peptide, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gp100+peptide/TGF+beta+1%2FTGFB1%2C+Human/pm40730154-858-119-120
    Average 95 stars, based on 1 article reviews
    human medchemexpress hy p70543 human gp100 peptide - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    human gp100 peptide kvprnqdwl  (GenScript corporation)
    90
    GenScript corporation human gp100 peptide kvprnqdwl
    Human Gp100 Peptide Kvprnqdwl, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gp100+peptide/gp100+peptide/pmc10140615__mmc4-153-171-175
    Average 90 stars, based on 1 article reviews
    human gp100 peptide kvprnqdwl - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    gp100 peptide vaccine  (Agenus Inc)
    86
    Agenus Inc gp100 peptide vaccine
    Gp100 Peptide Vaccine, supplied by Agenus Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gp100+peptide/neoantigen+peptide+personalized+vaccine/pm40733649-310-7-13
    Average 86 stars, based on 1 article reviews
    gp100 peptide vaccine - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    antigenic peptide gp100 154-162  (Genaxxon BioScience GmbH)
    90
    Genaxxon BioScience GmbH antigenic peptide gp100 154-162
    Delivery of <t>gp100</t> on mannosylated HJ scaffolds into moLCs for antigen presentation. A ) Reaction scheme for gp100-functionalization of Q2 and Q4 with NHS-DBCO ( 1 ), followed by SPAAC reaction to azide-modified ( pink ) Val-Cit-PAB-linked ( yellow) gp100 ( red ) ( 2 ). B ) Schematic representation of gp100-conjugated HJs employed for antigen presentation. C ) Visual representation of the antigen-presentation assay using moLCs incubated with gp100-conjugated HJs to facilitate receptor-mediated endocytosis ( I ), followed by release of gp100 in the lysosomes ( II ) and presentation of gp100 on HLA-A2 ( III ). Subsequently, moLCs were co-cultured with wildtype- or gp100 Jurkat cells to verify antigen presentation by T cell activation. D ) IL-2 concentration (pg/mL) in the co-culture media by ELISA. Results shown from four independent human donors were expressed by the mean ± SD. Statistical analysis was conducted by a one-way ANOVA followed by a Tukey’s post hoc test. E ) Antigen-presentation assay comparing HJ-3xTriMan-1xgp100 assembled with either a cleavable linker ( Val-Cit ) or a non-cleavable linker. Results shown from three independent human donors were expressed by the mean ± SD. Statistical analysis was conducted by a two-way t test. p-value * = <0.05, ** = <0.01, *** = <0.001, ****= <0.0001.
    Antigenic Peptide Gp100 154 162, supplied by Genaxxon BioScience GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gp100+peptide/antigenic+peptide+gp100+154+162/bio_rxiv__2025__06__04__657560-175-0-8
    Average 90 stars, based on 1 article reviews
    antigenic peptide gp100 154-162 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    gp100 peptides  (AnaSpec)
    90
    AnaSpec gp100 peptides
    Delivery of <t>gp100</t> on mannosylated HJ scaffolds into moLCs for antigen presentation. A ) Reaction scheme for gp100-functionalization of Q2 and Q4 with NHS-DBCO ( 1 ), followed by SPAAC reaction to azide-modified ( pink ) Val-Cit-PAB-linked ( yellow) gp100 ( red ) ( 2 ). B ) Schematic representation of gp100-conjugated HJs employed for antigen presentation. C ) Visual representation of the antigen-presentation assay using moLCs incubated with gp100-conjugated HJs to facilitate receptor-mediated endocytosis ( I ), followed by release of gp100 in the lysosomes ( II ) and presentation of gp100 on HLA-A2 ( III ). Subsequently, moLCs were co-cultured with wildtype- or gp100 Jurkat cells to verify antigen presentation by T cell activation. D ) IL-2 concentration (pg/mL) in the co-culture media by ELISA. Results shown from four independent human donors were expressed by the mean ± SD. Statistical analysis was conducted by a one-way ANOVA followed by a Tukey’s post hoc test. E ) Antigen-presentation assay comparing HJ-3xTriMan-1xgp100 assembled with either a cleavable linker ( Val-Cit ) or a non-cleavable linker. Results shown from three independent human donors were expressed by the mean ± SD. Statistical analysis was conducted by a two-way t test. p-value * = <0.05, ** = <0.01, *** = <0.001, ****= <0.0001.
    Gp100 Peptides, supplied by AnaSpec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gp100+peptide/gp100+peptide/pm40199327-253-63-65
    Average 90 stars, based on 1 article reviews
    gp100 peptides - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    gp100 peptide  (AnaSpec)
    90
    AnaSpec gp100 peptide
    Delivery of <t>gp100</t> on mannosylated HJ scaffolds into moLCs for antigen presentation. A ) Reaction scheme for gp100-functionalization of Q2 and Q4 with NHS-DBCO ( 1 ), followed by SPAAC reaction to azide-modified ( pink ) Val-Cit-PAB-linked ( yellow) gp100 ( red ) ( 2 ). B ) Schematic representation of gp100-conjugated HJs employed for antigen presentation. C ) Visual representation of the antigen-presentation assay using moLCs incubated with gp100-conjugated HJs to facilitate receptor-mediated endocytosis ( I ), followed by release of gp100 in the lysosomes ( II ) and presentation of gp100 on HLA-A2 ( III ). Subsequently, moLCs were co-cultured with wildtype- or gp100 Jurkat cells to verify antigen presentation by T cell activation. D ) IL-2 concentration (pg/mL) in the co-culture media by ELISA. Results shown from four independent human donors were expressed by the mean ± SD. Statistical analysis was conducted by a one-way ANOVA followed by a Tukey’s post hoc test. E ) Antigen-presentation assay comparing HJ-3xTriMan-1xgp100 assembled with either a cleavable linker ( Val-Cit ) or a non-cleavable linker. Results shown from three independent human donors were expressed by the mean ± SD. Statistical analysis was conducted by a two-way t test. p-value * = <0.05, ** = <0.01, *** = <0.001, ****= <0.0001.
    Gp100 Peptide, supplied by AnaSpec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gp100+peptide/gp100+peptide/pm40158231-118-6-11
    Average 90 stars, based on 1 article reviews
    gp100 peptide - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    gp10025 33 peptide  (MedChemExpress)
    93
    MedChemExpress gp10025 33 peptide
    Delivery of <t>gp100</t> on mannosylated HJ scaffolds into moLCs for antigen presentation. A ) Reaction scheme for gp100-functionalization of Q2 and Q4 with NHS-DBCO ( 1 ), followed by SPAAC reaction to azide-modified ( pink ) Val-Cit-PAB-linked ( yellow) gp100 ( red ) ( 2 ). B ) Schematic representation of gp100-conjugated HJs employed for antigen presentation. C ) Visual representation of the antigen-presentation assay using moLCs incubated with gp100-conjugated HJs to facilitate receptor-mediated endocytosis ( I ), followed by release of gp100 in the lysosomes ( II ) and presentation of gp100 on HLA-A2 ( III ). Subsequently, moLCs were co-cultured with wildtype- or gp100 Jurkat cells to verify antigen presentation by T cell activation. D ) IL-2 concentration (pg/mL) in the co-culture media by ELISA. Results shown from four independent human donors were expressed by the mean ± SD. Statistical analysis was conducted by a one-way ANOVA followed by a Tukey’s post hoc test. E ) Antigen-presentation assay comparing HJ-3xTriMan-1xgp100 assembled with either a cleavable linker ( Val-Cit ) or a non-cleavable linker. Results shown from three independent human donors were expressed by the mean ± SD. Statistical analysis was conducted by a two-way t test. p-value * = <0.05, ** = <0.01, *** = <0.001, ****= <0.0001.
    Gp10025 33 Peptide, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gp100+peptide/Gp100+(25-33)%2C+mouse/10__1158_slash_0008___5472__can___24___2982-81-41-43
    Average 93 stars, based on 1 article reviews
    gp10025 33 peptide - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    human gp100 peptide  (AnaSpec)
    90
    AnaSpec human gp100 peptide
    (A) Body weight (percentage change from baseline) of mice (n=8 mice/group) treated with PBS, IL-9 (50 µg or 100 µg), or IL-2 (50 µg) i.p. every other day. (B) Survival of mice from (A). (C) Sum of distance traveled over 30 second period in mice from (A), plotted relative to the average distance traveled by mice in the PBS group. (D) Graphical representation of mouse movement (n=8 mice/group) over a period of 30 seconds at baseline (top panel) and six days after starting treatment (bottom panel). (E) Serum IFNγ levels measured by ELISA six days after initiating treatment (n=3 mice/group) as described in A-C. (F) B16-F10 tumor growth (mean ± SEM, n=5 mice/group) after ACT with <t>pmel</t> T cells engineered with o9R or IL-9R (0.4×10 6 transduced cells, i.v.), and cytokine treatment with oIL-2 or IL-9, respectively (5×10 4 IU i.p., daily for 5 days starting with ACT). Data is representative of three independent experiments. (G) Survival of mice from (F). (H) Quantification of transduced pmel T cells in the blood five days after ACT (n=5 mice/group). (I) Quantification of transduced pmel T cells (Thy1.1 + YFP + ) across different tissues five days after ACT (n=5 mice/group). (J) Transduced (YFP + ) pmel T cells as percentage of all pmel T cells within the tumor 14 days after ACT (left panel) and total number of CD8+ T cells per gram of tumor 14 days after ACT (right panel) (n=5 mice per group). (K) o9R or IL9R transduced C57BL/6 T cells stimulated for 24h with IL-2 (10nM), IL-9 (10nM), oIL-2 (10µM), or a combination as noted. The proportion of naïve (CD62L+CD44-), central memory (CD62L+CD44+), effector (CD44+CD62L-) or double negative (CD62L-CD44-) T cells. Data from two independent experiments, with 4 technical replicates per condition. (L) The proportion of T SCM cells (CD44-, CD62L+, Sca-1+) from (K). For in vivo experiments, cytokines were tagged with mouse serum albumin (MSA) for half-life extension. *P < 0.05, **P < 0.005, ***P < 0.0005, ****P < 0.0001 (one-way ANOVA for A-C and E-F; Mantel-Cox for G; unpaired t test for H and J, two-way ANOVA for K-L).
    Human Gp100 Peptide, supplied by AnaSpec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gp100+peptide/gp100+peptide/bio_rxiv__2025__01__15__633105-282-20-24
    Average 90 stars, based on 1 article reviews
    human gp100 peptide - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    mouse gp100 peptide as-64752  (AnaSpec)
    90
    AnaSpec mouse gp100 peptide as-64752
    Analysis of OT-1 splenocytes after treatment with a conventional protocol or PDCNP-Ab (n = 3 biologically independent samples). a Analysis of T-cell activation markers, including CD69, TNF-α, and IFN-γ, and memory T cell phenotypes. b Analysis of T-cell proliferation and differentiation into T CM or T EM . c Scheme of testing adoptive cell therapy with PDCNP-Ab loaded OT-1 cells in mice bearing flank B16F10-OVA tumors. PBS or OT-1 splenocytes (8 × 10 6 /mouse), activated with either a conventional protocol or with PDCNP-Ab, were fused i.v. into animals 7 days after tumor inoculation (n = 5 mice). Created in BioRender. Li, J. (2024) https://BioRender.com/j90x668 . d Animal survival (left) and tumor growth curves (right). e Scheme of testing adoptive cell therapy with PDCNP-Ab-loaded <t>PMEL-1</t> T cells. The study was conducted in a metastatic tumor model established with i.v. administered B16F10-fluc cells. PBS or splenocytes from PMEL-1 mice (8 × 10 6 /mouse), activated with either a conventional protocol or with PDCNP-Ab, were fused i.v. into animals 7 days after tumor inoculation (n = 5 mice). Created in BioRender. Li, J. (2024) https://BioRender.com/d83g701 . f Whole-body bioluminescence images taken at different time points to monitor tumor establishment and metastasis. g Left, tumor growth curves, based on region-of-interest (ROI) analysis of BLI images; right, animal survival curves. Data represent mean ± SD. Statistical difference was evaluated using a one-way ANOVA test in ( a – b ); Mantel-Cox test in ( d , g ) (survival); and unpaired t-test (one-tailed) in ( d, g ) (tumor volume). Source data underlying ( a – b, d and g ) are provided in a file.
    Mouse Gp100 Peptide As 64752, supplied by AnaSpec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gp100+peptide/gp100+peptide/pmc11582315-436-15-20
    Average 90 stars, based on 1 article reviews
    mouse gp100 peptide as-64752 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Delivery of gp100 on mannosylated HJ scaffolds into moLCs for antigen presentation. A ) Reaction scheme for gp100-functionalization of Q2 and Q4 with NHS-DBCO ( 1 ), followed by SPAAC reaction to azide-modified ( pink ) Val-Cit-PAB-linked ( yellow) gp100 ( red ) ( 2 ). B ) Schematic representation of gp100-conjugated HJs employed for antigen presentation. C ) Visual representation of the antigen-presentation assay using moLCs incubated with gp100-conjugated HJs to facilitate receptor-mediated endocytosis ( I ), followed by release of gp100 in the lysosomes ( II ) and presentation of gp100 on HLA-A2 ( III ). Subsequently, moLCs were co-cultured with wildtype- or gp100 Jurkat cells to verify antigen presentation by T cell activation. D ) IL-2 concentration (pg/mL) in the co-culture media by ELISA. Results shown from four independent human donors were expressed by the mean ± SD. Statistical analysis was conducted by a one-way ANOVA followed by a Tukey’s post hoc test. E ) Antigen-presentation assay comparing HJ-3xTriMan-1xgp100 assembled with either a cleavable linker ( Val-Cit ) or a non-cleavable linker. Results shown from three independent human donors were expressed by the mean ± SD. Statistical analysis was conducted by a two-way t test. p-value * = <0.05, ** = <0.01, *** = <0.001, ****= <0.0001.

    Journal: bioRxiv

    Article Title: Targeting Langerhans cells using a modular mannosylated nucleic acid-based vaccine platform

    doi: 10.1101/2025.06.04.657560

    Figure Lengend Snippet: Delivery of gp100 on mannosylated HJ scaffolds into moLCs for antigen presentation. A ) Reaction scheme for gp100-functionalization of Q2 and Q4 with NHS-DBCO ( 1 ), followed by SPAAC reaction to azide-modified ( pink ) Val-Cit-PAB-linked ( yellow) gp100 ( red ) ( 2 ). B ) Schematic representation of gp100-conjugated HJs employed for antigen presentation. C ) Visual representation of the antigen-presentation assay using moLCs incubated with gp100-conjugated HJs to facilitate receptor-mediated endocytosis ( I ), followed by release of gp100 in the lysosomes ( II ) and presentation of gp100 on HLA-A2 ( III ). Subsequently, moLCs were co-cultured with wildtype- or gp100 Jurkat cells to verify antigen presentation by T cell activation. D ) IL-2 concentration (pg/mL) in the co-culture media by ELISA. Results shown from four independent human donors were expressed by the mean ± SD. Statistical analysis was conducted by a one-way ANOVA followed by a Tukey’s post hoc test. E ) Antigen-presentation assay comparing HJ-3xTriMan-1xgp100 assembled with either a cleavable linker ( Val-Cit ) or a non-cleavable linker. Results shown from three independent human donors were expressed by the mean ± SD. Statistical analysis was conducted by a two-way t test. p-value * = <0.05, ** = <0.01, *** = <0.001, ****= <0.0001.

    Article Snippet: Antigenic peptide gp100 154-162 (sequence: KTWGQYWQV, specificity: HLA-A*02:01, GENAXXON bioscience) was conjugated to the oligonucleotide strands in a 2-step one-pot reaction.

    Techniques: Immunopeptidomics, Modification, Incubation, Cell Culture, Activation Assay, Concentration Assay, Co-Culture Assay, Enzyme-linked Immunosorbent Assay

    (A) Body weight (percentage change from baseline) of mice (n=8 mice/group) treated with PBS, IL-9 (50 µg or 100 µg), or IL-2 (50 µg) i.p. every other day. (B) Survival of mice from (A). (C) Sum of distance traveled over 30 second period in mice from (A), plotted relative to the average distance traveled by mice in the PBS group. (D) Graphical representation of mouse movement (n=8 mice/group) over a period of 30 seconds at baseline (top panel) and six days after starting treatment (bottom panel). (E) Serum IFNγ levels measured by ELISA six days after initiating treatment (n=3 mice/group) as described in A-C. (F) B16-F10 tumor growth (mean ± SEM, n=5 mice/group) after ACT with pmel T cells engineered with o9R or IL-9R (0.4×10 6 transduced cells, i.v.), and cytokine treatment with oIL-2 or IL-9, respectively (5×10 4 IU i.p., daily for 5 days starting with ACT). Data is representative of three independent experiments. (G) Survival of mice from (F). (H) Quantification of transduced pmel T cells in the blood five days after ACT (n=5 mice/group). (I) Quantification of transduced pmel T cells (Thy1.1 + YFP + ) across different tissues five days after ACT (n=5 mice/group). (J) Transduced (YFP + ) pmel T cells as percentage of all pmel T cells within the tumor 14 days after ACT (left panel) and total number of CD8+ T cells per gram of tumor 14 days after ACT (right panel) (n=5 mice per group). (K) o9R or IL9R transduced C57BL/6 T cells stimulated for 24h with IL-2 (10nM), IL-9 (10nM), oIL-2 (10µM), or a combination as noted. The proportion of naïve (CD62L+CD44-), central memory (CD62L+CD44+), effector (CD44+CD62L-) or double negative (CD62L-CD44-) T cells. Data from two independent experiments, with 4 technical replicates per condition. (L) The proportion of T SCM cells (CD44-, CD62L+, Sca-1+) from (K). For in vivo experiments, cytokines were tagged with mouse serum albumin (MSA) for half-life extension. *P < 0.05, **P < 0.005, ***P < 0.0005, ****P < 0.0001 (one-way ANOVA for A-C and E-F; Mantel-Cox for G; unpaired t test for H and J, two-way ANOVA for K-L).

    Journal: bioRxiv

    Article Title: IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy

    doi: 10.1101/2025.01.15.633105

    Figure Lengend Snippet: (A) Body weight (percentage change from baseline) of mice (n=8 mice/group) treated with PBS, IL-9 (50 µg or 100 µg), or IL-2 (50 µg) i.p. every other day. (B) Survival of mice from (A). (C) Sum of distance traveled over 30 second period in mice from (A), plotted relative to the average distance traveled by mice in the PBS group. (D) Graphical representation of mouse movement (n=8 mice/group) over a period of 30 seconds at baseline (top panel) and six days after starting treatment (bottom panel). (E) Serum IFNγ levels measured by ELISA six days after initiating treatment (n=3 mice/group) as described in A-C. (F) B16-F10 tumor growth (mean ± SEM, n=5 mice/group) after ACT with pmel T cells engineered with o9R or IL-9R (0.4×10 6 transduced cells, i.v.), and cytokine treatment with oIL-2 or IL-9, respectively (5×10 4 IU i.p., daily for 5 days starting with ACT). Data is representative of three independent experiments. (G) Survival of mice from (F). (H) Quantification of transduced pmel T cells in the blood five days after ACT (n=5 mice/group). (I) Quantification of transduced pmel T cells (Thy1.1 + YFP + ) across different tissues five days after ACT (n=5 mice/group). (J) Transduced (YFP + ) pmel T cells as percentage of all pmel T cells within the tumor 14 days after ACT (left panel) and total number of CD8+ T cells per gram of tumor 14 days after ACT (right panel) (n=5 mice per group). (K) o9R or IL9R transduced C57BL/6 T cells stimulated for 24h with IL-2 (10nM), IL-9 (10nM), oIL-2 (10µM), or a combination as noted. The proportion of naïve (CD62L+CD44-), central memory (CD62L+CD44+), effector (CD44+CD62L-) or double negative (CD62L-CD44-) T cells. Data from two independent experiments, with 4 technical replicates per condition. (L) The proportion of T SCM cells (CD44-, CD62L+, Sca-1+) from (K). For in vivo experiments, cytokines were tagged with mouse serum albumin (MSA) for half-life extension. *P < 0.05, **P < 0.005, ***P < 0.0005, ****P < 0.0001 (one-way ANOVA for A-C and E-F; Mantel-Cox for G; unpaired t test for H and J, two-way ANOVA for K-L).

    Article Snippet: Isolated pmel T cells were activated with 100 U ml -1 recombinant mouse IL-2 (rmIL-2) (Peprotech) and 1 µg ml -1 human gp100 peptide (Anaspec) the day before transduction.

    Techniques: Enzyme-linked Immunosorbent Assay, In Vivo

    (A) Tumor growth (from ) with data shown for individual mice. (B) B16-F10 tumor growth (mean ± SEM, n=5 mice/group) in mice treated with either PBS or IL-9 (5×10 4 IU, i.p/dose) starting five days after tumor inoculation and continuing every other day for five doses. (C) KP-gp100 tumor growth (mean ± SEM and individual mice, n=6 mice / group) after ACT with pmel T cells engineered with IL-9R (1.6×10 6 transduced cells, i.v.), and cytokine treatment with PBS or IL-9, respectively (5×10 4 IU i.p., every other day for 5 days starting with ACT). Data is representative of two independent experiments. (D) Quantification of transduced pmel T cells (Thy1.1 + YFP + ) across different tissues 14 days after ACT and five doses of MSA-oIL2 or MSA-mIL9 (n=5 mice/group). (E) Representative gating strategy of CD44 and CD62L phenotyping for IL-9R or o9R-engineered T cells 24h after stimulation with IL-2 (10nM), IL-9 (10nM), or MSA-oIL2 (10µM). See . (F) Related to . The percentage of naïve (CD62L+CD44-), central memory (CD62L+CD44+), effector (CD44+CD62L-) or double negative (CD62L-CD44-) T cells as bar plots. (G) Proportion of T SCM cells (CD44-, CD62L+, Sca-1+) from (E) presented as bar plots. For all in vivo experiments, cytokines were tagged with mouse serum albumin (MSA) for half-life extension. *P < 0.05, **P < 0.005, ***P < 0.0005, ****P < 0.0001 (two-way ANOVA for B; Welch’s T-test for C; one-way ANOVA for D; two-way ANOVA for F-G).

    Journal: bioRxiv

    Article Title: IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy

    doi: 10.1101/2025.01.15.633105

    Figure Lengend Snippet: (A) Tumor growth (from ) with data shown for individual mice. (B) B16-F10 tumor growth (mean ± SEM, n=5 mice/group) in mice treated with either PBS or IL-9 (5×10 4 IU, i.p/dose) starting five days after tumor inoculation and continuing every other day for five doses. (C) KP-gp100 tumor growth (mean ± SEM and individual mice, n=6 mice / group) after ACT with pmel T cells engineered with IL-9R (1.6×10 6 transduced cells, i.v.), and cytokine treatment with PBS or IL-9, respectively (5×10 4 IU i.p., every other day for 5 days starting with ACT). Data is representative of two independent experiments. (D) Quantification of transduced pmel T cells (Thy1.1 + YFP + ) across different tissues 14 days after ACT and five doses of MSA-oIL2 or MSA-mIL9 (n=5 mice/group). (E) Representative gating strategy of CD44 and CD62L phenotyping for IL-9R or o9R-engineered T cells 24h after stimulation with IL-2 (10nM), IL-9 (10nM), or MSA-oIL2 (10µM). See . (F) Related to . The percentage of naïve (CD62L+CD44-), central memory (CD62L+CD44+), effector (CD44+CD62L-) or double negative (CD62L-CD44-) T cells as bar plots. (G) Proportion of T SCM cells (CD44-, CD62L+, Sca-1+) from (E) presented as bar plots. For all in vivo experiments, cytokines were tagged with mouse serum albumin (MSA) for half-life extension. *P < 0.05, **P < 0.005, ***P < 0.0005, ****P < 0.0001 (two-way ANOVA for B; Welch’s T-test for C; one-way ANOVA for D; two-way ANOVA for F-G).

    Article Snippet: Isolated pmel T cells were activated with 100 U ml -1 recombinant mouse IL-2 (rmIL-2) (Peprotech) and 1 µg ml -1 human gp100 peptide (Anaspec) the day before transduction.

    Techniques: In Vivo

    (A) Dose-response curves of STAT1, STAT3, and STAT5 phosphorylation in IL-9R or o9R transduced (YFP + ) pmel T cells stimulated with either oIL-2 or IL-9 for 20 minutes (shown are technical duplicates; representative of at least three independent experiments). (B) Volcano plots depicting differential gene expression based on RNA-sequencing of IL-9R or o9R transduced C57BL/6 T cells and treated with IL-9 (10 nM), IL-2 (10 nM) or oIL2 (10 µM) for 48 hours. Comparisons for each volcano plot are shown below the x-axis. Significance (red) indicates adjusted p < 10 -5 and absolute fold change ≥2. (C) Differentially phosphorylated proteins between IL-9R transduced C57BL/6 T cells stimulated for 20’ with either IL-2 (10nM) or no cytokine (left) or IL-9 (10nM) versus no cytokine (right). Significance (red) indicates adjusted p<0.05 and log 2 (fold change)≥ 0.5. (D) Dose-response curve for STAT4 phosphorylation among IL-9R transduced (YFP + ) pmel T cells treated for 20 minutes with IL-9 or IL-12, or o9R transduced T cells treated with oIL-2 (shown are technical duplicates; representative of two independent experiments). (E) Waterfall plot summarizing transcription factor enrichment scores based on RNA-seq data of IL-9R T cells treated with IL-9 or IL-2 (top 15 for each). Enrichment score is inferred by fitting a linear model that predicts observed gene expression based on prior knowledge of a curated set of transcription factors and their target genes. (F) Heat map of the expression of the Biocarta IL-12 Pathway gene set based on RNA-sequencing from (B). Samples and genes clustered hierarchically without supervision. (G) In vitro expansion of IL-9R (YFP + ) transduced pmel T cells and treated with 10nM cytokine starting on day 3 after activation (n=3 technical replicates/group). Data is representative of three biological replicates and two independent experiments. (H) Representative contour plots of CD44 and CD62L expression of T cells from (G) after 24h treatment with cytokine. (I) Quantification of naïve CD62L + CD44 - (left) and stem-like CD62L + CD44 - Sca-1 + (right) T cells from (H). Data from two independent experiments. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 (one-way ANOVA for G; two-way ANOVA for G, I).

    Journal: bioRxiv

    Article Title: IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy

    doi: 10.1101/2025.01.15.633105

    Figure Lengend Snippet: (A) Dose-response curves of STAT1, STAT3, and STAT5 phosphorylation in IL-9R or o9R transduced (YFP + ) pmel T cells stimulated with either oIL-2 or IL-9 for 20 minutes (shown are technical duplicates; representative of at least three independent experiments). (B) Volcano plots depicting differential gene expression based on RNA-sequencing of IL-9R or o9R transduced C57BL/6 T cells and treated with IL-9 (10 nM), IL-2 (10 nM) or oIL2 (10 µM) for 48 hours. Comparisons for each volcano plot are shown below the x-axis. Significance (red) indicates adjusted p < 10 -5 and absolute fold change ≥2. (C) Differentially phosphorylated proteins between IL-9R transduced C57BL/6 T cells stimulated for 20’ with either IL-2 (10nM) or no cytokine (left) or IL-9 (10nM) versus no cytokine (right). Significance (red) indicates adjusted p<0.05 and log 2 (fold change)≥ 0.5. (D) Dose-response curve for STAT4 phosphorylation among IL-9R transduced (YFP + ) pmel T cells treated for 20 minutes with IL-9 or IL-12, or o9R transduced T cells treated with oIL-2 (shown are technical duplicates; representative of two independent experiments). (E) Waterfall plot summarizing transcription factor enrichment scores based on RNA-seq data of IL-9R T cells treated with IL-9 or IL-2 (top 15 for each). Enrichment score is inferred by fitting a linear model that predicts observed gene expression based on prior knowledge of a curated set of transcription factors and their target genes. (F) Heat map of the expression of the Biocarta IL-12 Pathway gene set based on RNA-sequencing from (B). Samples and genes clustered hierarchically without supervision. (G) In vitro expansion of IL-9R (YFP + ) transduced pmel T cells and treated with 10nM cytokine starting on day 3 after activation (n=3 technical replicates/group). Data is representative of three biological replicates and two independent experiments. (H) Representative contour plots of CD44 and CD62L expression of T cells from (G) after 24h treatment with cytokine. (I) Quantification of naïve CD62L + CD44 - (left) and stem-like CD62L + CD44 - Sca-1 + (right) T cells from (H). Data from two independent experiments. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 (one-way ANOVA for G; two-way ANOVA for G, I).

    Article Snippet: Isolated pmel T cells were activated with 100 U ml -1 recombinant mouse IL-2 (rmIL-2) (Peprotech) and 1 µg ml -1 human gp100 peptide (Anaspec) the day before transduction.

    Techniques: Expressing, RNA Sequencing Assay, In Vitro, Activation Assay

    (A) Principal component analysis (PC1 vs PC2) of RNA sequencing of C57BL/6 T cells transduced for 48h with IL-9R and treated with IL-9 (10 nM) or IL-2 (10 nM), or with o9R and treated with oIL2 (10 µM). Samples cluster by treatment. (B) Volcano plots depicting differential gene expression based on RNA-sequencing of C57BL/6 T cells transduced with IL-9R or o9R and treated with IL-9 (10 nM), IL-2 (10 nM) or oIL2 (10 µM) for 48 hours. Shown here is the comparisons between o9R T cells treated with oIL-2 and IL-9R T cells treated with IL-2. Significance (red) indicates adjusted p-value < 1 x 10 -5 . (C) Heatmap of top 100 differentially upregulated (left) and downregulated (right) transcripts in T cell expressing IL-9R treated with IL-9 versus IL-2 for 48h. Shown also are the o9R samples treated with oIL-2, which mimic the expression of the IL-9R + IL-9 samples. (D) Differentially phosphorylated proteins between C57BL/6 T cells transduced with IL-9R and stimulated with IL-2 (10nM) or IL-9 for 20’. Significance (red) indicates adjusted p < 0.05 and log 2 (fold change) ≥ 0.5. (E) Representative gating strategy for flow cytometry data for intracellular staining of phosphoproteins in engineered (YFP + ) T cells. (F) Dose-response curves of ERK or AKT phosphorylation in IL-9R or o9R transduced pmel T cells (YFP + ) and stimulated with either oIL-2, IL-2, or IL-9 for 20 minutes. Error bars represent min/max of technical duplicates. Data representative of two independent experiments.

    Journal: bioRxiv

    Article Title: IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy

    doi: 10.1101/2025.01.15.633105

    Figure Lengend Snippet: (A) Principal component analysis (PC1 vs PC2) of RNA sequencing of C57BL/6 T cells transduced for 48h with IL-9R and treated with IL-9 (10 nM) or IL-2 (10 nM), or with o9R and treated with oIL2 (10 µM). Samples cluster by treatment. (B) Volcano plots depicting differential gene expression based on RNA-sequencing of C57BL/6 T cells transduced with IL-9R or o9R and treated with IL-9 (10 nM), IL-2 (10 nM) or oIL2 (10 µM) for 48 hours. Shown here is the comparisons between o9R T cells treated with oIL-2 and IL-9R T cells treated with IL-2. Significance (red) indicates adjusted p-value < 1 x 10 -5 . (C) Heatmap of top 100 differentially upregulated (left) and downregulated (right) transcripts in T cell expressing IL-9R treated with IL-9 versus IL-2 for 48h. Shown also are the o9R samples treated with oIL-2, which mimic the expression of the IL-9R + IL-9 samples. (D) Differentially phosphorylated proteins between C57BL/6 T cells transduced with IL-9R and stimulated with IL-2 (10nM) or IL-9 for 20’. Significance (red) indicates adjusted p < 0.05 and log 2 (fold change) ≥ 0.5. (E) Representative gating strategy for flow cytometry data for intracellular staining of phosphoproteins in engineered (YFP + ) T cells. (F) Dose-response curves of ERK or AKT phosphorylation in IL-9R or o9R transduced pmel T cells (YFP + ) and stimulated with either oIL-2, IL-2, or IL-9 for 20 minutes. Error bars represent min/max of technical duplicates. Data representative of two independent experiments.

    Article Snippet: Isolated pmel T cells were activated with 100 U ml -1 recombinant mouse IL-2 (rmIL-2) (Peprotech) and 1 µg ml -1 human gp100 peptide (Anaspec) the day before transduction.

    Techniques: RNA Sequencing Assay, Expressing, Transduction, Flow Cytometry, Staining

    (A) Sequence alignment between mouse and human IL-2, IL-9, IL-15, and IL-21 around the conserved glutamine in Helix D. (B) Waterfall plot of maximal tumor size reduction for experiment from , in which B16-F10 tumors in mice (n=7-9 mice/group) treated with IL-9R transduced pmel T cells and either IL-9 WT or IL-9 Q115T . (C) Peripheral blood enrichment of IL-9R transduced pmel T cells over time in mice treated with ACT and either IL-9 WT or IL-9 Q115T cytokine (each cytokine dose indicated by a vertical dashed line). Enrichment was calculated as percentage of transduced (YFP+) pmel T cells as a proportion of all pmel T cells. See also . (D) Dose-response curves of phosphorylation of indicated STAT proteins in pmel T cells transduced with IL-9R WT , IL-9R 3x , and IL-9R 5x and stimulated with IL-2 or IL-9 for 20 minutes. Error bars represent min/max of three biological replicates. For in vivo experiments, cytokines were tagged with mouse serum albumin (MSA) for half-life extension. ***P < 0.001 (Welch’s t-test for C, two-way ANOVA for D).

    Journal: bioRxiv

    Article Title: IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy

    doi: 10.1101/2025.01.15.633105

    Figure Lengend Snippet: (A) Sequence alignment between mouse and human IL-2, IL-9, IL-15, and IL-21 around the conserved glutamine in Helix D. (B) Waterfall plot of maximal tumor size reduction for experiment from , in which B16-F10 tumors in mice (n=7-9 mice/group) treated with IL-9R transduced pmel T cells and either IL-9 WT or IL-9 Q115T . (C) Peripheral blood enrichment of IL-9R transduced pmel T cells over time in mice treated with ACT and either IL-9 WT or IL-9 Q115T cytokine (each cytokine dose indicated by a vertical dashed line). Enrichment was calculated as percentage of transduced (YFP+) pmel T cells as a proportion of all pmel T cells. See also . (D) Dose-response curves of phosphorylation of indicated STAT proteins in pmel T cells transduced with IL-9R WT , IL-9R 3x , and IL-9R 5x and stimulated with IL-2 or IL-9 for 20 minutes. Error bars represent min/max of three biological replicates. For in vivo experiments, cytokines were tagged with mouse serum albumin (MSA) for half-life extension. ***P < 0.001 (Welch’s t-test for C, two-way ANOVA for D).

    Article Snippet: Isolated pmel T cells were activated with 100 U ml -1 recombinant mouse IL-2 (rmIL-2) (Peprotech) and 1 µg ml -1 human gp100 peptide (Anaspec) the day before transduction.

    Techniques: Sequencing, Transduction, In Vivo

    (A) Structural prediction of the interleukin-9 (IL-9) receptor complex based on AlphaFold2. The complex consists of the IL-9 receptor (IL-9R, green), IL-9 (blue), and the γ c (pink). The inset demonstrates the interaction of the glutamine at amino acid position 115 of IL-9 (Q115) with the γ c , which we subsequently mutated (IL-9 Q115T ) to generate an attenuated cytokine. (B) Dose-response curves of STAT1, STAT3, STAT4, and STAT5 phosphorylation in IL-9R transduced pmel T cells stimulated with IL-9 WT (blue) or IL-9 Q115T (light gray) for 20 minutes. Error bars represent SEM of technical duplicates; Data is representative of two independent experiments. (C) Tumor growth after ACT with IL-9R pmel T cells seven days after B16-F10 tumor inoculation. Mice were treated with either IL-9 WT (n=7 mice) or IL-9 Q115T (n=9 mice) (10 doses, every other day). Data is representative of two independent experiments. (D) Peripheral blood quantification of IL-9R transduced pmel T cells over time in mice treated with ACT and either IL-9 WT or IL-9 Q115T cytokine (each cytokine dose indicated by a vertical dashed line). In the IL-9 Q115T group, IL-9R pmel T cells were not observed in the blood at day 41 or after three additional cytokine doses on days 44-48, and thus only the IL-9 WT group received doses beyond day 48. Data is representative of two independent experiments. (E) Schematic of IL-9R variants with either three (IL-9R 3x ) or five (IL-9R 5x ) repeated phospho-tyrosine (pY) elements within the intracellular domain of the IL-9 receptor (created with Biorender.com ). Sequence of the phosphotyrosine element shown in the legend. (F) Phosphorylation of indicated STATs at E max (100nM) for IL-9R WT , IL-9R 3x , and IL-9R 5x transduced pmel T cells stimulated with IL-2 or IL-9 for 20 minutes. Data is representative of three biological experiments (mean ± SEM). (G) B16-F10 tumor growth after ACT with either IL-9R WT (n=7 mice) or IL-9R 3x transduced pmel T cells (n=8 mice). Mice were also treated with IL-9 (5×10 4 IU i.p., every other day for 5 doses starting with ACT). Shown are individual tumor growth curves (left and middle) and mean ± SEM (right). Data is representative of two independent experiments. For in vivo experiments, cytokines were tagged with mouse serum albumin (MSA) for half-life extension. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001. (two-way ANOVA for C; Welch’s t-test for D, G; one-way ANOVA for F). See also .

    Journal: bioRxiv

    Article Title: IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy

    doi: 10.1101/2025.01.15.633105

    Figure Lengend Snippet: (A) Structural prediction of the interleukin-9 (IL-9) receptor complex based on AlphaFold2. The complex consists of the IL-9 receptor (IL-9R, green), IL-9 (blue), and the γ c (pink). The inset demonstrates the interaction of the glutamine at amino acid position 115 of IL-9 (Q115) with the γ c , which we subsequently mutated (IL-9 Q115T ) to generate an attenuated cytokine. (B) Dose-response curves of STAT1, STAT3, STAT4, and STAT5 phosphorylation in IL-9R transduced pmel T cells stimulated with IL-9 WT (blue) or IL-9 Q115T (light gray) for 20 minutes. Error bars represent SEM of technical duplicates; Data is representative of two independent experiments. (C) Tumor growth after ACT with IL-9R pmel T cells seven days after B16-F10 tumor inoculation. Mice were treated with either IL-9 WT (n=7 mice) or IL-9 Q115T (n=9 mice) (10 doses, every other day). Data is representative of two independent experiments. (D) Peripheral blood quantification of IL-9R transduced pmel T cells over time in mice treated with ACT and either IL-9 WT or IL-9 Q115T cytokine (each cytokine dose indicated by a vertical dashed line). In the IL-9 Q115T group, IL-9R pmel T cells were not observed in the blood at day 41 or after three additional cytokine doses on days 44-48, and thus only the IL-9 WT group received doses beyond day 48. Data is representative of two independent experiments. (E) Schematic of IL-9R variants with either three (IL-9R 3x ) or five (IL-9R 5x ) repeated phospho-tyrosine (pY) elements within the intracellular domain of the IL-9 receptor (created with Biorender.com ). Sequence of the phosphotyrosine element shown in the legend. (F) Phosphorylation of indicated STATs at E max (100nM) for IL-9R WT , IL-9R 3x , and IL-9R 5x transduced pmel T cells stimulated with IL-2 or IL-9 for 20 minutes. Data is representative of three biological experiments (mean ± SEM). (G) B16-F10 tumor growth after ACT with either IL-9R WT (n=7 mice) or IL-9R 3x transduced pmel T cells (n=8 mice). Mice were also treated with IL-9 (5×10 4 IU i.p., every other day for 5 doses starting with ACT). Shown are individual tumor growth curves (left and middle) and mean ± SEM (right). Data is representative of two independent experiments. For in vivo experiments, cytokines were tagged with mouse serum albumin (MSA) for half-life extension. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001. (two-way ANOVA for C; Welch’s t-test for D, G; one-way ANOVA for F). See also .

    Article Snippet: Isolated pmel T cells were activated with 100 U ml -1 recombinant mouse IL-2 (rmIL-2) (Peprotech) and 1 µg ml -1 human gp100 peptide (Anaspec) the day before transduction.

    Techniques: Sequencing, In Vivo

    (A) Schematic of the IL-9 receptor complex, highlighting the phosphotyrosine residue within the IL-9R intracellular domain (ICD) and three adjacent amino acids. A panel of ten single amino acid mutations were generated within the ICD at the proline or glutamine residues (created with Biorender.com ). (B) Heat map of MFI (log-scaled and row-scaled) at E max for phosphorylation of STAT1, STAT3, STAT4, and STAT5 for C57BL/6 T cells transduced with wildtype IL-9R or one of ten IL-9R mutants. Transduced pmel T cells (technical duplicates) were stimulated with IL-9 for 20 minutes. Data is representative of two independent experiments. (C) Dose-response curves of STAT1, STAT3, STAT4, and STAT5 phosphorylation among transduced IL-9R WT , IL-9R AQ , and IL-9R PR pmel T cells (YFP+) stimulated with recombinant IL-9 for 20 minutes. Error bars represent SEM of technical duplicates. Data is representative of three biological replicates. (D) Relative in vitro expansion of YFP + IL-9R WT , IL-9R AQ , IL-9R PR pmel T cells cultured with IL-9 on day 3 post-activation (10 nM; n=3 technical replicates/group). Data is representative of 3 biological replicates. (E) In vitro proliferation index of C57BL/6 T cells engineered with IL-9R WT , IL-9R AQ , and IL-9R PR over the course of nine days post-activation (transduced on day 1), as measured by dilution of CellTrace Violet dye (n=6 replicates/group). Cells were treated with either recombinant IL-2 or IL-9 (10 nM) on day 3 after T cell activation. Proliferation index was quantified using FlowJo software based on values of histogram peaks (see ). (F) Peripheral blood quantification of IL-9R WT , IL-9R AQ , or IL-9R PR transduced (Thy1.1 + YFP + ) pmel T cells in B16-F10 tumor-bearing mice (n=6-7 mice/group) on the indicated days after ACT. IL-9 treatment (5×10 4 IU i.p., every other day) was started with ACT and continued for 5 doses. Data is representative of at least three independent experiments. (G) Quantification of IL-9R WT , IL-9R AQ , or IL-9R PR transduced (YFP+) pmel T cells within the tumors (B16-F10) of mice (n=6-7 mice/group) seven days post adoptive cell transfer (ACT). Data is representative of two independent experiments. (H) B16-F10 tumor growth in mice treated with IL-9R WT (n=7 mice) or IL-9R PR (n=6 mice) pmel T cells. Data is representative of at least three independent experiments. (I) B16-F10 tumor growth in mice treated with IL-9R WT or IL-9R AQ pmel T cells (n=10 mice/group). IL-9 treatment as per (F). Data is representative of at least 4 independent experiments. For in vivo experiments, cytokines were tagged with mouse serum albumin (MSA) for half-life extension. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 (two-way ANOVA for D-F; Welch’s t-test for G-I).

    Journal: bioRxiv

    Article Title: IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy

    doi: 10.1101/2025.01.15.633105

    Figure Lengend Snippet: (A) Schematic of the IL-9 receptor complex, highlighting the phosphotyrosine residue within the IL-9R intracellular domain (ICD) and three adjacent amino acids. A panel of ten single amino acid mutations were generated within the ICD at the proline or glutamine residues (created with Biorender.com ). (B) Heat map of MFI (log-scaled and row-scaled) at E max for phosphorylation of STAT1, STAT3, STAT4, and STAT5 for C57BL/6 T cells transduced with wildtype IL-9R or one of ten IL-9R mutants. Transduced pmel T cells (technical duplicates) were stimulated with IL-9 for 20 minutes. Data is representative of two independent experiments. (C) Dose-response curves of STAT1, STAT3, STAT4, and STAT5 phosphorylation among transduced IL-9R WT , IL-9R AQ , and IL-9R PR pmel T cells (YFP+) stimulated with recombinant IL-9 for 20 minutes. Error bars represent SEM of technical duplicates. Data is representative of three biological replicates. (D) Relative in vitro expansion of YFP + IL-9R WT , IL-9R AQ , IL-9R PR pmel T cells cultured with IL-9 on day 3 post-activation (10 nM; n=3 technical replicates/group). Data is representative of 3 biological replicates. (E) In vitro proliferation index of C57BL/6 T cells engineered with IL-9R WT , IL-9R AQ , and IL-9R PR over the course of nine days post-activation (transduced on day 1), as measured by dilution of CellTrace Violet dye (n=6 replicates/group). Cells were treated with either recombinant IL-2 or IL-9 (10 nM) on day 3 after T cell activation. Proliferation index was quantified using FlowJo software based on values of histogram peaks (see ). (F) Peripheral blood quantification of IL-9R WT , IL-9R AQ , or IL-9R PR transduced (Thy1.1 + YFP + ) pmel T cells in B16-F10 tumor-bearing mice (n=6-7 mice/group) on the indicated days after ACT. IL-9 treatment (5×10 4 IU i.p., every other day) was started with ACT and continued for 5 doses. Data is representative of at least three independent experiments. (G) Quantification of IL-9R WT , IL-9R AQ , or IL-9R PR transduced (YFP+) pmel T cells within the tumors (B16-F10) of mice (n=6-7 mice/group) seven days post adoptive cell transfer (ACT). Data is representative of two independent experiments. (H) B16-F10 tumor growth in mice treated with IL-9R WT (n=7 mice) or IL-9R PR (n=6 mice) pmel T cells. Data is representative of at least three independent experiments. (I) B16-F10 tumor growth in mice treated with IL-9R WT or IL-9R AQ pmel T cells (n=10 mice/group). IL-9 treatment as per (F). Data is representative of at least 4 independent experiments. For in vivo experiments, cytokines were tagged with mouse serum albumin (MSA) for half-life extension. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 (two-way ANOVA for D-F; Welch’s t-test for G-I).

    Article Snippet: Isolated pmel T cells were activated with 100 U ml -1 recombinant mouse IL-2 (rmIL-2) (Peprotech) and 1 µg ml -1 human gp100 peptide (Anaspec) the day before transduction.

    Techniques: Residue, Generated, Transduction, Recombinant, In Vitro, Cell Culture, Activation Assay, Software, In Vivo

    (A) Schematic for in vivo experiment to generate single cell RNAseq data. IL-9R WT , IL-9R AQ , or IL-9R PR engineered pmel T cells are adoptively transferred into B16-F10 tumor-bearing mice seven days after tumor inoculation. Mice (n=7-8 mice/group) are treated with IL-9 (5×10 4 I.U. every other day) starting on the day of ACT (day 7) until tumors are harvested on day 15. Transduced pmel T cells (Thy1.1 + YFP + ) are sorted by FACS prior to library preparation and single cell RNAseq. See related – . (B) UMAP plots based on scRNAseq of n=6,706 cells pmel T cells from (A). Ten major clusters colored according to annotation. See related . (C) Propeller plots demonstrating the relative proportion of each cluster from (A), split by treatment group (IL-9R WT , IL-9R AQ , or IL-9R PR ). (D) Violin plots summarizing single cell expression of a gene set differentially expressed between KLRG1 hi effector and naïve mouse T cells (GSE10239). Gene sets are summarized as a module score in Seurat and plotted by treatment group. (E) Violin plots summarizing single cell expression of a gene set differentially expressed between mouse T cells eight days (D8) after encounter with acute infection versus malignancy (GSE60501). Gene sets are summarized as a module score in Seurat and plotted by treatment group. (F) Ridgeplot of pseudotime scores for single cell data from (A) organized by treatment group. (G) UMAP plot of scRNA-sequencing data from (A) annotated with pseudotime trajectories. Cells within the Tscm-like (Tcf7) cluster were selected as the root for the pseudotime analysis (white circles with black outlines). Black circles with white outlines represent nodes of the differentiation trajectory. (H) Schematic for linking phosphoflow data with RNA-sequencing data. o9R, IL-9R WT , IL-9R AQ , IL-9R PR , or IL-9R 5x pmel T cells were treated with cytokines for either 20 mins (phosphoflow) or 48h (RNA-sequencing). MFIs at E max for pSTAT1, pSTAT3, pSTAT4 and pSTAT5 were merged with RNA-sequencing data to identify genes highly correlated with phosphorylation of each STAT protein. (I) Histograms of phosphorylation of STAT1, STAT3, STAT4 and STAT5 for transduced (YFP+) T cells for each condition after 20 minutes of cytokine stimulation at Emax: IL-2 (10nM), IL-9 (10nM) and oIL-2 (10μM). (J) Venn diagram of the top 100 genes most correlated with the phosphorylation of each STAT. (K) Scatterplot depicting the relationship between the pSTAT1 module score (y-axis) and pSTAT1 phosphorylation levels (x-axis) in vitro. Module score was calculated from the expression of 100 genes most strongly correlated with STAT1 phosphorylation in vitro. Shown are biological triplicates for the gene expression data, colored by sample condition. For STAT phosphorylation data, shown are the average of technical replicates. The gray line indicates the linear regression fit. (L) Violin plot depicting projection of pSTAT1 module score from (J)-(K) onto scRNA-seq data from (A), organized by treatment group. (M) Projection of pSTAT1 module score from (J)-(K) onto UMAP of scRNA-seq data from (A). (N) Waterfall plot summarizing transcription factor (TF) enrichment scores when comparing in vitro RNAseq data of IL-9R WT vs IL-9R AQ groups (left) and IL-9R PR vs IL-9R WT groups (right). Gene expression changes across IL-9R AQ ➔ IL-9R WT ➔ IL-9R PR are captured by increasing activity of STAT1 and related TFs (shown in red). (O) Ridgeplots summarizing STAT1, STAT3, STAT4, and STAT5a regulon activity as an AUC score calculated using SCENIC. Results are presented by treatment group, with pairwise statistical comparisons (Wilcoxon Rank-Sum Test).

    Journal: bioRxiv

    Article Title: IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy

    doi: 10.1101/2025.01.15.633105

    Figure Lengend Snippet: (A) Schematic for in vivo experiment to generate single cell RNAseq data. IL-9R WT , IL-9R AQ , or IL-9R PR engineered pmel T cells are adoptively transferred into B16-F10 tumor-bearing mice seven days after tumor inoculation. Mice (n=7-8 mice/group) are treated with IL-9 (5×10 4 I.U. every other day) starting on the day of ACT (day 7) until tumors are harvested on day 15. Transduced pmel T cells (Thy1.1 + YFP + ) are sorted by FACS prior to library preparation and single cell RNAseq. See related – . (B) UMAP plots based on scRNAseq of n=6,706 cells pmel T cells from (A). Ten major clusters colored according to annotation. See related . (C) Propeller plots demonstrating the relative proportion of each cluster from (A), split by treatment group (IL-9R WT , IL-9R AQ , or IL-9R PR ). (D) Violin plots summarizing single cell expression of a gene set differentially expressed between KLRG1 hi effector and naïve mouse T cells (GSE10239). Gene sets are summarized as a module score in Seurat and plotted by treatment group. (E) Violin plots summarizing single cell expression of a gene set differentially expressed between mouse T cells eight days (D8) after encounter with acute infection versus malignancy (GSE60501). Gene sets are summarized as a module score in Seurat and plotted by treatment group. (F) Ridgeplot of pseudotime scores for single cell data from (A) organized by treatment group. (G) UMAP plot of scRNA-sequencing data from (A) annotated with pseudotime trajectories. Cells within the Tscm-like (Tcf7) cluster were selected as the root for the pseudotime analysis (white circles with black outlines). Black circles with white outlines represent nodes of the differentiation trajectory. (H) Schematic for linking phosphoflow data with RNA-sequencing data. o9R, IL-9R WT , IL-9R AQ , IL-9R PR , or IL-9R 5x pmel T cells were treated with cytokines for either 20 mins (phosphoflow) or 48h (RNA-sequencing). MFIs at E max for pSTAT1, pSTAT3, pSTAT4 and pSTAT5 were merged with RNA-sequencing data to identify genes highly correlated with phosphorylation of each STAT protein. (I) Histograms of phosphorylation of STAT1, STAT3, STAT4 and STAT5 for transduced (YFP+) T cells for each condition after 20 minutes of cytokine stimulation at Emax: IL-2 (10nM), IL-9 (10nM) and oIL-2 (10μM). (J) Venn diagram of the top 100 genes most correlated with the phosphorylation of each STAT. (K) Scatterplot depicting the relationship between the pSTAT1 module score (y-axis) and pSTAT1 phosphorylation levels (x-axis) in vitro. Module score was calculated from the expression of 100 genes most strongly correlated with STAT1 phosphorylation in vitro. Shown are biological triplicates for the gene expression data, colored by sample condition. For STAT phosphorylation data, shown are the average of technical replicates. The gray line indicates the linear regression fit. (L) Violin plot depicting projection of pSTAT1 module score from (J)-(K) onto scRNA-seq data from (A), organized by treatment group. (M) Projection of pSTAT1 module score from (J)-(K) onto UMAP of scRNA-seq data from (A). (N) Waterfall plot summarizing transcription factor (TF) enrichment scores when comparing in vitro RNAseq data of IL-9R WT vs IL-9R AQ groups (left) and IL-9R PR vs IL-9R WT groups (right). Gene expression changes across IL-9R AQ ➔ IL-9R WT ➔ IL-9R PR are captured by increasing activity of STAT1 and related TFs (shown in red). (O) Ridgeplots summarizing STAT1, STAT3, STAT4, and STAT5a regulon activity as an AUC score calculated using SCENIC. Results are presented by treatment group, with pairwise statistical comparisons (Wilcoxon Rank-Sum Test).

    Article Snippet: Isolated pmel T cells were activated with 100 U ml -1 recombinant mouse IL-2 (rmIL-2) (Peprotech) and 1 µg ml -1 human gp100 peptide (Anaspec) the day before transduction.

    Techniques: In Vivo, Expressing, Infection, Sequencing, RNA Sequencing Assay, In Vitro, Activity Assay

    (A) Tumor growth (mean ± SEM) for the experiment described in (A). Data is representative of at least two independent experiments. (B) Transduced (Thy1.1 + YFP + ) pmel T cells as a percentage of total CD8 T cells in the tumor by treatment group for scRNAseq experiment from (A)-(B). (C) Merged UMAP plot based on scRNAseq of of n=6,706 cells pmel T cells transduced with IL-9R WT , IL-9R AQ , or IL-9R PR . Ten major clusters colored according to annotation. See related . (D) Violin plots summarizing single cell expression of stem and memory markers, Tcf7 (top) and Il7r (bottom), by cluster. (E) Feature plot of module score defined by the Gene Ontology Myeloid Differentiation gene set demonstrating high expression exclusively in the Tmyeloid-like cluster. (F) Violin plots summarizing single cell expression of effector molecules, Prf1 (top) and Gzmb (bottom), by treatment group. (G) Ridgeplot of pseudotime scores for single cell data from (A) organized by annotated cluster. (H) Scatterplot depicting the relationship between the pSTAT module scores (y-axis) and pSTAT phosphorylation levels (x-axis) in vitro. Module scores were calculated from the expression of 100 genes most strongly correlated with STAT phosphorylation in vitro. Shown are biological triplicates for the gene expression data, colored by sample condition. For STAT phosphorylation data, shown are the averages of technical duplicates. See also . (I) Projection of pSTAT module scores from (H) onto scRNA-seq data from . (J) Hallmark gene set enrichment analysis based on genes differentially expressed among tumor infiltrating IL-9R AQ pmel T cells from .

    Journal: bioRxiv

    Article Title: IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy

    doi: 10.1101/2025.01.15.633105

    Figure Lengend Snippet: (A) Tumor growth (mean ± SEM) for the experiment described in (A). Data is representative of at least two independent experiments. (B) Transduced (Thy1.1 + YFP + ) pmel T cells as a percentage of total CD8 T cells in the tumor by treatment group for scRNAseq experiment from (A)-(B). (C) Merged UMAP plot based on scRNAseq of of n=6,706 cells pmel T cells transduced with IL-9R WT , IL-9R AQ , or IL-9R PR . Ten major clusters colored according to annotation. See related . (D) Violin plots summarizing single cell expression of stem and memory markers, Tcf7 (top) and Il7r (bottom), by cluster. (E) Feature plot of module score defined by the Gene Ontology Myeloid Differentiation gene set demonstrating high expression exclusively in the Tmyeloid-like cluster. (F) Violin plots summarizing single cell expression of effector molecules, Prf1 (top) and Gzmb (bottom), by treatment group. (G) Ridgeplot of pseudotime scores for single cell data from (A) organized by annotated cluster. (H) Scatterplot depicting the relationship between the pSTAT module scores (y-axis) and pSTAT phosphorylation levels (x-axis) in vitro. Module scores were calculated from the expression of 100 genes most strongly correlated with STAT phosphorylation in vitro. Shown are biological triplicates for the gene expression data, colored by sample condition. For STAT phosphorylation data, shown are the averages of technical duplicates. See also . (I) Projection of pSTAT module scores from (H) onto scRNA-seq data from . (J) Hallmark gene set enrichment analysis based on genes differentially expressed among tumor infiltrating IL-9R AQ pmel T cells from .

    Article Snippet: Isolated pmel T cells were activated with 100 U ml -1 recombinant mouse IL-2 (rmIL-2) (Peprotech) and 1 µg ml -1 human gp100 peptide (Anaspec) the day before transduction.

    Techniques: Transduction, Expressing, In Vitro

    Analysis of OT-1 splenocytes after treatment with a conventional protocol or PDCNP-Ab (n = 3 biologically independent samples). a Analysis of T-cell activation markers, including CD69, TNF-α, and IFN-γ, and memory T cell phenotypes. b Analysis of T-cell proliferation and differentiation into T CM or T EM . c Scheme of testing adoptive cell therapy with PDCNP-Ab loaded OT-1 cells in mice bearing flank B16F10-OVA tumors. PBS or OT-1 splenocytes (8 × 10 6 /mouse), activated with either a conventional protocol or with PDCNP-Ab, were fused i.v. into animals 7 days after tumor inoculation (n = 5 mice). Created in BioRender. Li, J. (2024) https://BioRender.com/j90x668 . d Animal survival (left) and tumor growth curves (right). e Scheme of testing adoptive cell therapy with PDCNP-Ab-loaded PMEL-1 T cells. The study was conducted in a metastatic tumor model established with i.v. administered B16F10-fluc cells. PBS or splenocytes from PMEL-1 mice (8 × 10 6 /mouse), activated with either a conventional protocol or with PDCNP-Ab, were fused i.v. into animals 7 days after tumor inoculation (n = 5 mice). Created in BioRender. Li, J. (2024) https://BioRender.com/d83g701 . f Whole-body bioluminescence images taken at different time points to monitor tumor establishment and metastasis. g Left, tumor growth curves, based on region-of-interest (ROI) analysis of BLI images; right, animal survival curves. Data represent mean ± SD. Statistical difference was evaluated using a one-way ANOVA test in ( a – b ); Mantel-Cox test in ( d , g ) (survival); and unpaired t-test (one-tailed) in ( d, g ) (tumor volume). Source data underlying ( a – b, d and g ) are provided in a file.

    Journal: Nature Communications

    Article Title: Calcium nanoparticles target and activate T cells to enhance anti-tumor function

    doi: 10.1038/s41467-024-54402-y

    Figure Lengend Snippet: Analysis of OT-1 splenocytes after treatment with a conventional protocol or PDCNP-Ab (n = 3 biologically independent samples). a Analysis of T-cell activation markers, including CD69, TNF-α, and IFN-γ, and memory T cell phenotypes. b Analysis of T-cell proliferation and differentiation into T CM or T EM . c Scheme of testing adoptive cell therapy with PDCNP-Ab loaded OT-1 cells in mice bearing flank B16F10-OVA tumors. PBS or OT-1 splenocytes (8 × 10 6 /mouse), activated with either a conventional protocol or with PDCNP-Ab, were fused i.v. into animals 7 days after tumor inoculation (n = 5 mice). Created in BioRender. Li, J. (2024) https://BioRender.com/j90x668 . d Animal survival (left) and tumor growth curves (right). e Scheme of testing adoptive cell therapy with PDCNP-Ab-loaded PMEL-1 T cells. The study was conducted in a metastatic tumor model established with i.v. administered B16F10-fluc cells. PBS or splenocytes from PMEL-1 mice (8 × 10 6 /mouse), activated with either a conventional protocol or with PDCNP-Ab, were fused i.v. into animals 7 days after tumor inoculation (n = 5 mice). Created in BioRender. Li, J. (2024) https://BioRender.com/d83g701 . f Whole-body bioluminescence images taken at different time points to monitor tumor establishment and metastasis. g Left, tumor growth curves, based on region-of-interest (ROI) analysis of BLI images; right, animal survival curves. Data represent mean ± SD. Statistical difference was evaluated using a one-way ANOVA test in ( a – b ); Mantel-Cox test in ( d , g ) (survival); and unpaired t-test (one-tailed) in ( d, g ) (tumor volume). Source data underlying ( a – b, d and g ) are provided in a file.

    Article Snippet: PMEL-1 splenocytes were collected from PMEL-1 mice as previously described and activated by incubation with mouse gp100 peptide (10 μg/mL, AnaSpec, AS-64752) and mouse IL-2 (10 ng/mL) for 5 days.

    Techniques: Activation Assay, One-tailed Test